首页> 外文期刊>Drug delivery. >Preparation and in vitro and in vivo evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate
【24h】

Preparation and in vitro and in vivo evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate

机译:甘草次酸硬脂酯修饰的10-羟基喜树碱脂质体的制备及体外和体内评价

获取原文
           

摘要

10-Hydroxycamptothecin (HCPT) liposomes surface modified with stearyl glycyrrhetinate (SG) were prepared by the film dispersion method. Characterization of the liposomes, including drug release in vitro, pharmacokinetics and tissue distribution, was done. HCPT in plasma and tissues was determined by high-performance liquid chromatography (HPLC). Compared with the conventional HCPT-liposomes and commercially available hydroxycamptothecin injection (HCPT Inject), pharmacokinetic parameters indicated that SG-HCPT-liposomes had better bioavailability. Regarding tissue distribution, the concentration of HCPT loaded by SG modified liposomes in the liver was higher than other tissues and the risk to the kidney was lower than HCPT-liposomes and HCPT Inject. These results support the hypothesis that the HCPT-liposomes modified with SG show enhanced liver-targeting through the glycyrrhetinic acid (GA) receptor to be an efficient drug carrier, which may help to improve therapeutic methods for hepatic diseases in the future.
机译:通过薄膜分散法制备了经硬脂酸甘草次酸酯(SG)表面改性的10-羟基喜树碱(HCPT)脂质体。对脂质体进行了表征,包括体外药物释放,药代动力学和组织分布。血浆和组织中的HCPT通过高效液相色谱(HPLC)测定。与常规HCPT-脂质体和市售的羟基喜树碱注射液(HCPT Inject)相比,药代动力学参数表明SG-HCPT-脂质体具有更好的生物利用度。就组织分布而言,SG修饰的脂质体在肝脏中负载的HCPT浓度高于其他组织,对肾脏的风险低于HCPT-脂质体和HCPT注射剂。这些结果支持以下假设:用SG修饰的HCPT脂质体通过甘草次酸(GA)受体显示出增强的肝靶向性,成为有效的药物载体,这可能有助于将来改善肝病的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号